Tradestie Institutional Equity Comparison Engine

CRSP vs TDOC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TDOC Overall Edge

TDOC Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Teladoc Health, Inc. (TDOC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus TDOC at N/M Forward P/E and -5.4% operating margin (-3.4% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against TDOC sits in CONSOLIDATION (40th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs TDOC N/M Fwd P/E
Growth & Margin Winner TDOC
Op Margin -2058.6% vs -5.4% ยท YoY +1325.1% vs -3.4%
Momentum & Technical Winner TDOC
1Y -20.5% vs +21.4% ยท 52W Pos 1% vs 76%
Options & Structure Winner TDOC
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (40th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
TDOC NYSE
Teladoc Health, Inc.
Services-Offices & Clinics Of Doctors Of Medicine
$8.59
-2.44% 1D
Market Cap $1.6B
1M Return +51.41%
1Y Return +21.43%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 24.0 Fund 36.0 Flow 58.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% TDOC +21.43% Spread: +41.97 pp (TDOC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue TDOC Revenue CRSP Op. Margin TDOC Op. Margin Margin Edge
FY2018 $0M $420M -5087.8% -17.0% TDOC
FY2019 $290M $550M 16.1% -14.5% CRSP
FY2020 $0M $1.09B -49295.5% -46.3% TDOC
FY2021 $910M $2.03B 40.8% -13.1% CRSP
FY2022 $0M $2.41B -56190.4% -567.3% TDOC
FY2023 $370M $2.60B -60.0% -9.6% TDOC
FY2024 $40M $2.57B -1250.4% -39.7% TDOC
FY2025 $0M $2.53B -18933.6% -10.4% TDOC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (7) vs TDOC (3)
Institutional Metric CRSP TDOC Criterion Row Winner
Market Capitalization Scale $4.1B $1.6B Larger Scale CRSP
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% -3.4% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -5.4% Higher Margin TDOC
Net Profit Margin Profitability 0.0% -6.3% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -25.6% -11.5% Higher ROE TDOC
52-Week Range Position Momentum 1% ($40โ€“$63) 76% ($4โ€“$10) Stronger Trend TDOC
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 0.83ฮฒ ยท 108% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs TDOC Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TDOC CONSOLIDATION
93d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 40th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live TDOC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor TDOC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.